The aim of this study was to determine the value of the lactulosemannitol intestinal permeability test in screening the general adult population for unrecognized enteropathy and latent coeliac disease.
INTRODUCTION
Measures of intestinal permeability using the dual sugar method reflect damage to the mucosal barrier and have been used in investigating and screening for small intestinal disease. I This is due to a consistent increase in the absorption of disaccharide (lactuloser'" and a reduction in the absorption of monosaccharide (mannitol)"? after the ingestion of a solution containing the sugar probe molecules. Intestinal permeability tests are non-invasive, well tolerated and safe for patients to perform. They can be performed on an out-patient basis and the results are reproducible."
The use of these tests in children and adults with symptomatic coeliac disease is well recognized.",12 However, since intestinal permeability is almost invariably raised in untreated coeliac disease, the intestinal permeability test has been proposed as one of the best screening tests for this condition.P:" Cobden has reported the cellobiose-mannitol test to be a sensitive, accurate test and superior to other, currently used screening tests for coeliac disease, compared with o-xylose absorption, IgA-antireticulin antibodies and serum folate." The lactulosemannitol protocol is comparable to the cellobiose-mannitol protocol, with a sensitivity of 89%, specificity of 54% and negative predictive value of 95%. 13 On this basis the test could be suitable for use as a screening test for large patient populations.
The lactulose-rnannitol protocol has been extended to screening first-degree relatives for coeliac disease. 16 Vogelsang et al. reported that 34 (3 I %) of I I I first-degree relatives of coeliac disease patients had an elevated lactulosemannitol excretion ratio (LMER), nine of whom also had anti-endomysial antibodies (EMA). All nine had villous atrophy on jejunal biopsy. A combination of these two tests is proposed for screening in this 'at-risk' group. In addition, Catassi has applied the intestinal permeability test to screening for coeliac disease in a random sample of the teenage population although the sensitivity of the test was only 45% in that group of patients." No previous studies have examined the use of the lactulose-rnannitol intestinal permeability test in detecting coeliac disease in a random sample of the general adult population.
The use of serological screening tests has also been proposed as a means of identifying asymptomatic patients or those with unrecognized coeliac disease in the general population. The latter term is preferred since we have found that the majority of coeliac subjects diagnosed following screening are not asymptomatic.l" As a follow-up to population screening we identified that at least 1:122 of subjects between 24-65 years in our population had enteropathy." However there appears to be a large number of 'false positives', namely subjects with positive serology on screening and normal jejunal histology. We have reported that the majority of subjects with antibodies associated with coeliac disease develop negative serology after 3 years and have a normal jejunal biopsy; we have termed this pattern 'transient serology'." The pattern of subjects with a normal jejunal biopsy but with at least one of the three antibodies remaining positive we have termed 'persistent serology'. The question arises whether these individuals have gluten sensitivity in which the mucosal changes are subtle and at the mild end of the spectrum. One previous study has suggested that this may be the case" and recognized markers of this latent form of coeliac disease include raised intestinal permeability, intraepitheliallymphocyte levels and y-o T cell levels in jejunal biopsies. 22 24 Latent coeliac disease implies that the disease is indicated by these immunopathological markers but that it has not yet clinically manifested itself.
The aim of this study was to determine whether intestinal permeability is raised as an indicator of latent coeliac disease in subjects who have transient or persistent serology and normal histology, and to compare our use of the permeability test to the serological assays.
MATERIALS AND METHODS

MONICA subjects
In Northern Ireland the Belfast MONICA (Multinational MONItoring of trends and determinants in CArdiovascular disease) project was set up as part of a multi-centred, international study to determine risk factors for coronary heart disease in the adult population. The sample population was selected at random by means of a computer programme from patients contained on the Northern Ireland Central Service Agency's General Practitioners' list, stratified to include equal numbers of each gender in the age range 25-64 years.
Subjects with positive serology [IgA antigliadin (AGA), IgA antiendomysial (EMA) and/or IgA antireticulin (ARA) antibodies) detected by population screening and age-and sex-matched controls recruited from the MONICA survey were asked to complete the intestinal permeability test and give consent for jejunal biopsy. Written consent was obtained from all patients after a full and informed description of the tests to be carried out. Coeliac disease was diagnosed on the basis of severe partial or sub-total villous atrophy on jejunal biopsy. Of 60 subjects with positive serology who completed the permeability test and consented to jejunal biopsy, there were 15 coeliac disease subjects (six men, nine women, mean age 51·1 years), 13 subjects with persistent serology (three men, ten women, mean age 50·7 years) and 32 with transient serology (21 men, 11 women, mean age 49·2 years). Of 65 serology-negative controls who completed the permeability test, 17 (six men, 11 women, mean age 50·6 years) consented to jejunal biopsy.
Evaluation of serological markers
Serum samples were taken as part of the initial screening of MONICA subjects for serum cholesterol. These samples were centrifuged, aliquoted and stored at -70°C until tested. Serological testing was carried out during 1994 and the clinical follow-up of MONICA subjects was performed between 1994 and 1996.
Determination of IgA antibodies to gliadin was carried out by enzyme-linked immunosorbent assay (ELISA; Labmaster, Turku, Finland). Results were expressed in ELISA units (EU) with a normal range of 0-99 (97'5 th centile).
Using indirect immunofluorescence, serum samples were initially screened at a dilution of I:20 for the presence of antireticulin antibody of the RI type (ARA) in the IgA class using composite sections of rat liver, kidney and mouse stomach (BioDiagnostics Ltd, Worcestershire, UK) and fluorescein-conjugated antihuman globulin (Dako Ltd, Buckinghamshire, UK). Positive serum samples were titrated further.
The IgA EMA was detected by indirect immunofluorescence using monkey oesophagus (BioOiagnostics Ltd) as antigen. Serum samples were initially tested at a dilution of 1:2 and any positives tested at dilutions I:5, I: 10, I:20and 1:40. Positivity was taken as a titre of 1:5or greater.
Lactulose-mannitol intestinal permeability test
All intestinal permeability tests were carried out on an out-patient basis and were performed 1-6 months prior to the jejunal biopsy. After a 6-h overnight fast, a pre-test urine sample was collected and the bladder was emptied completely. Subjects consumed a solution containing 5g lactulose, 2 g mannitol and 22·3 g glucose (as an osmotic filler) dissolved in 100mL water. The osmolarity of the test solution was 1500 mOsmol/L. All urine passed for the following 5 h was collected in a 2·5 L urine container. No food was allowed for the duration of the test, although water was permitted 2 h after the test solution had been consumed. At the end of the 5-h period the bladder was emptied completely into the urine container to end the test. The volume of the urine collection was recorded and both pre-test and test samples were preserved at -20°C until analysed. All patients on non-steroid anti-inflammatory drugs (NSAIOs) were noted.
Urinary estimations oflactulose and mannitol were measured by the enzymatic analyses described by Northrop et al. 25 and Lunn et al., 26 respectively, modified for use on the Cobas Fara centrifugal analyser (Roche Ltd, Welwyn Garden City, UK). The LMER was calculated by means of the following ratio after correction for basal samples:
Validation of lactulose-mannitol excretion ratio
The lactulose-mannitol intestinal permeability test was carried out in 21 healthy controls (10 men, II women, mean age 34·0 years) with no significant gastrointestinal symptoms who were not taking NSAIDs. Ten healthy controls (four men, six women, mean age 35·0 years) agreed to perform the lactulose-rnannitol protocol on two occasions to assess the degree of inter-biological variation. Intra-biological variation was assessed by one healthy control who performed the test on 10 different occasions. The interassay percentage coefficients of variation (%CVs) were assessed by repeated assays of 22 control samples. Sixteen untreated symptomatic Ann Clin Biochem 2000: 37 coeliac disease patients (five men, II women, mean age 46·2 years) and seven treated coeliac disease patients (four men, three women, mean age 43·6 years) recruited from the gastroenterology outpatient clinic of the Royal Victoria Hospital were compared with the healthy control group and were used to validate the permeability test.
The normal range was established from 21 healthy controls. Since the distribution of LMER was non-parametric, a log-transformation was carried out to determine the mean and standard deviation (SO). The upper limit of normal (LMER=0'024) was taken to be mean + 1·28 SO of the log-transformed LMER (representing the 90% centile) for the healthy volunteer group. This centile is appropriate to use since there is a significant distinction between normal and high values of LMER, whereas low values are of no further clinical significance.
This study was approved by the Research Ethics Committee of the Queen's University of Belfast in February 1994.
Statistics
The Wilcoxon matched pairs test was used to compare LMER in the same controls at two time points. The Mann Whitney U-test was used to compare LMER between the MONICA controls, coeliac subjects and the serology subgroups. Sensitivity is defined as the percentage of coeliac disease patients with a positive test; specificity is defined as the percentage of those with normal histology who have a negative test.
RESULTS
Validation in control subjects
There were no significant differences between % lactulose excretion (%LE; 0·28 versus 0,38, P=0'28), % mannitol excretion (%ME; 18·2 versus 21·2, P=0'28) and LMER (0,016 versus 0,018, P=0-48) in 10 subjects who repeated the test at two different time points.
Intra-biological variation, in a single control subject in whom the test was performed 10 times, was found to be 57%, all results being within the normal range (LMER~0·024). The inter-assay %CV obtained with 22 replicates was 1·96 for mannitol at the level of 67·1 mg/ 100mL and 2·6 for lactulose at the level of 16·5mg/100mL. Analytical variation of the LMER was 7·2%. Analytical recovery of both assays was greater than 97%. • ' .
• •
Treated CD patients 
Comparison o]'lacrulosr-mannitol excretion ratio (LM ER) in healthy volunteers and in untreated and treated coeliac disease (CD) patients.
Sixty-five controls from the MONICA survey with negative serology were combined with 12 healthy controls in order to determine the influence of age on LMER. A weak association of LMER with age was seen, with r = O' 34, P=O·OOI (see Fig. I ).
Validation in the clinical situation
Mean %LE (0,85 versus 0,26, P<O·OOI) and mean LMER (0'105 versus 0,013, P<O'OOI) were significantly higher in the untreated symptomatic coeliac group compared with healthy controls (see untreated symptomatic coeliac patients did not differ significantly compared with healthy controls (21,0 versus 19,2, P = 0,08). Thirteen of 16 untreated symptomatic coeliac patients had a raised LMER, compared with two of 21 healthy controls (P<O·OOI). In the clinical setting LM ER has a sensitivity of 81% and a specificity of 90% for detecting untreated symptomatic coeliac disease (see Table I ).
Comparing treated to untreated symptomatic coeliac patients, 'Yo LE (0' 31 versus 0,85, P=0'02) and LMER (0,013 versus 0,105, P = 0'003) were significantly lower in the treated symptomatic coeliac patients (see Fig. 2 ). Mean %ME in the treated coeliac group did not differ significantly from the untreated symptomatic coeliac group (23·4 versus 21,0, P=0·29). None of the three parameters differed significantly between treated coeliac patients and the healthy controls (%LE 0·31 versus 0·26, P=O'77; %ME 23·3 versus 19·2, P=0'98; LMER 0·012 versus 0·013, P=0·61).
Comparison of subjects with coeliac disease, persistent and transient serology, with MONICA controls
In the coeliac subjects % LE (0,94 versus 0,31, P<O'OOI) and LMER (0·\2 versus 0,02, P=O'OOOI) were higher and %ME (13'4 versus 22,5, P=0'03) was lower when compared with MONICA controls (see Fig. 3 ). %LE, LMER and %ME did not differ significantly when the transient and persistent groups were compared in turn with MONICA controls (see Fig. 3 ). Four of 17 MONICA controls had an elevated LMER compared with five of 13in the persistent serology group (P=0'38) , nine of 32 in the transient serology group (P=0'73) and 13 of 15 coeliac subjects (P<O·OOI). %LE (0,39 versus 0'46, P = 0,96), LMER (0'024 versus 0,024, P=0'96) and %ME (I8'3 versus 21'3, P=0' 21) did not differ significantly between persistent and transient serology groups. The serological profiles of the coeliac subjects and those in the transient and persistent serology groups are indicated in Table 2 . Comparisons between the different serology subgroups are not possible because of the small numbers in each group. With regard to use of the permeability test as a screening tool, it has a sensitivity of 87% and a specificity of 71% in detecting unrecognized coeliac disease in the MONICA population (see Table I ). The negative and positive predictive values of the LMER test were 96% and 42%, respectively. The sensitivity and negative predictive value of the LMER were superior to those of the three serological tests in the screening situation. Of the three serological assays, EMA was more valuable compared with AGA and ARA, both of which had a low sensitivity (67% and 40%, respectively). The sensitivity of LMER in the screening situation is also superior to its use in the clinical situation (87% versus 81%; see Table I ).
Persistent Transient serology serology (n) (n)
In this study we have compared the use of the lactulose-mannitol intestinal permeability test in detecting coeliac disease in the clinical and screening setting. Our findings are based on reliable assays which have been adequately validated. Untreated, symptomatic coeliac disease was associated with a rise in %LE and LMER compared with healthy controls, which confirms the findings of several previous studies.e? The sensitivity of the test in the clinical situation was 81%, with a negative predictive value of 90%. When applied to screening of the general population the lactulose-mannitol test is of superior value, with a sensitivity of 87%. However, use of the test as a single screening test of the general adult population for coeliac disease would lead to approximately one in every seven coeliac patients being missed. The lactulose-mannitol test does however have a high negative predictive value (96%), necessary for an ideal screening test in order to exclude patients who are unlikely to have coeliac disease on the basis of a non-invasive test. This compares favourably with the use of the lactulose-mannitol protocol in a previous study. 13 We have found that the absorption of mannitol in untreated, symptomatic coeliac patients did not differ significantly compared with that of healthy controls. Catassi et al. have also demonstrated in their screening study that children with coeliac disease detected by screening do not have a significantly lower mannitol excretion compared with controls. 17 However, it is well recognized that the absorption/excretion of individual sugars is not, by itself, a reliable indicator of intestinal permeability. Instead, it is the disaccharide/monosaccharide ratio (LMER) which is useful in distinguishing coeliac patients from controls. We have confirmed that the LMER was significantly higher in both untreated, symptomatic coeliac patients compared with healthy controls and in MONICA coeliac subjects compared with MONICA controls. Combined with the adequate validation of our assays which we have demonstrated, this underlines that our results are a true representation of our study population.
Our main findings contrast with those recently reported by Catassi et al. 17 In this study an isosmolar solution containing lactulose and mannitol was used to investigate teenage subjects with coeliac disease detected as a follow-up to a serological screening survey. The sensitivity of the test was found to be 45% and the authors concluded that the lactulose-mannitol permeability test is not useful in screening for coeliac disease. The sensitivity of the lactulose-mannitol test in our follow-up screening study (87%) is substantially higher than this. Our use of a hyperosmolar test solution, which is known to produce a marked increase in lactulose absorption in untreated coeliac patients but only a small increase in normal controls, may account for this. 27 ,28 This method has been criticized on the basis that it is usually unnecessary, it is relatively unphysiological and it may lead to nausea or loose stools in some patients, although the sensitivity of the test is markedly improved, as we have demonstrated. No patients or controls included in this study reported any side effects from the hyperosmolar test solution. In addition, the age of our patients was 28-67 years, compared to 11-14 years in Catassi and colleagues' study, although this in itself is unlikely to account for the marked difference observed between the two studies. Our finding that intestinal permeability rises with age indicates the need for caution in comparing patient groups with different age distributions. An increase in intestinal permeability with age has previously been reported, although while the individual absorption of cellobiose and L-rhamnose was reduced in elderly inpatients aged 75-96 years, the cellobiose-rhamnose excretion ratio was similar to that in healthy controls (aged 22-64 years)." Age-associated deterioration in intestinal barrier function may lead to increased absorption of luminal antigens and this may be one explanation contributing to antigen-associated agerelated diseases."
We have also investigated the use of the lactulose-mannitol intestinal permeability test in subjects with persistent and transient serology to determine whether LMER was elevated as a marker of latent coeliac disease. Neither of these groups differed significantly from MONICA controls and it is apparent that apart from the persistently positive serology in the former group, there is no other evidence of latent coeliac disease. The reason for these false positive serological results remains to be established. We have recently reported that the mojority of these subjects develop negative serology when followed up after four and thirteen years!' and that an increased gluten Ann Clin Biochem 2000: 37 intake, particularly in the form of soda bread, may account for the transient serological markers for coeliac disease in these subjects. P We have found that the LMER as a screening test is superior to the three serological assays, primarily in terms of a higher sensitivity and negative predictive value, both of which are required for ideal screening tests. We have found EMA to be superior to both AGA and ARA in detecting coeliac disease in the MONICA population, although false positives and false negatives do still occur.
In summary, we have demonstrated that the lactulose-mannitol intestinal permeability test is a useful screening test for coeliac disease in the general adult population and compares favourably with its use in the clinical situation. Since the persistent and transient serology groups did not differ from MONICA controls it would appear that they do not have latent coeliac disease and are simply 'false positives'.
